Two Miami defendants received roughly 57‑month sentences for their roles in a scheme that diverted approximately $28 million in high‑priced prescription drugs through illicit channels and sold them, creating public‑health risks. Prosecutors noted misbranded and improperly stored medications were part of the conduct.

Federal prosecutors in the Southern District of Florida announced sentencing of two Miami men to approximately 57 months’ imprisonment each for participating in a multi‑million‑dollar operation that diverted high‑priced prescription pharmaceuticals and sold them through unauthorized channels. According to court filings and the DOJ release, the scheme involved redirecting medications intended for legitimate supply chains, misbranding products, and failing to maintain proper storage and handling — conduct that both defrauded payors and posed potential public‑health dangers. The diversion produced an estimated $28 million in revenue that prosecutors attributed to illicit distribution networks. Sentencing remarks emphasized the significant financial loss, the risk to patient safety from improperly handled drugs, and the need to deter similar conduct within regulated pharmaceutical supply chains. The case resulted in substantial federal prison terms and restitution considerations, reflecting coordinated investigative work to trace diverted inventory, identify participants, and hold individuals accountable for large‑scale schemes that combine fraud with risks to public health.